Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luvometinib Combined With Anlotinib in KRAS-mutated Metastatic NSCLC
NCT07562581Phase 2Recruiting
- Sponsor
- Fosun Pharma
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of luvometinib in non-small cell lung cancer (NSCLC), sponsored by Fosun Pharma. Started Jun 2026; status: recruiting.
02
Drugs
luvometinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07562581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07562581.